Sugi Predict

Sugi Predict / Compounds / SCHEMBL10000678

SCHEMBL10000678

SCHEMBL10000678

CCCCCCCCCCNCC(C)CC

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 4/20 0.52
▸ ALDH1A1 P00352 2/20 0.52
▸ ANPEP P15144 1/20 0.47
▸ ERAP2 Q6P179 1/20 0.47
▸ EPHX1 P07099 7/20 0.43
▸ ADH1B P00325 2/20 0.43
▸ ADH1C P00326 2/20 0.43
▸ ADH1A P07327 2/20 0.43
▸ ADH4 P08319 2/20 0.43
▸ ADH7 P40394 2/20 0.43
▸ S1PR2 O95136 5/20 0.39
▸ S1PR4 O95977 5/20 0.39
▸ S1PR1 P21453 5/20 0.39
▸ S1PR3 Q99500 5/20 0.39
▸ S1PR5 Q9H228 1/20 0.39
▸ CYP3A4 P08684 1/20 0.37
▸ THRB P10828 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20134437 1.00 TSHR (0.52) TSHRALDH1A1ANPEPERAP2EPHX1
SCHEMBL20281606 1.00 TSHR (0.52) TSHRALDH1A1ANPEPERAP2EPHX1
SCHEMBL7778097 1.00 TSHR (0.52) TSHRALDH1A1ANPEPERAP2EPHX1
SCHEMBL7775065 1.00 TSHR (0.52) TSHRALDH1A1ANPEPERAP2EPHX1
SCHEMBL20706483 1.00 TSHR (0.52) TSHRALDH1A1ANPEPERAP2EPHX1
Hydrochloric Acid SCHEMBL11121260 0.98 TSHR (0.50) TSHRALDH1A1ANPEPERAP2EPHX1
SCHEMBL7775105 0.98 TSHR (0.55) TSHRALDH1A1ANPEPERAP2EPHX1
SCHEMBL19827509 0.91 TSHR (0.48) TSHRALDH1A1ANPEPERAP2EPHX1
SCHEMBL6050098 0.91 TSHR (0.48) TSHRALDH1A1ANPEPERAP2EPHX1
SCHEMBL23308200 0.89 ALDH1A1 (0.44) TSHRALDH1A1ANPEPERAP2EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9566299-B2 Oral pharmaceutical composition of aliphatic amine polymer or salts thereof WOCKHARDT LIMITED (IN) 2017-02-14 — — US disclosed
US-9566299-B2 Oral pharmaceutical composition of aliphatic amine polymer or salts thereof WOCKHARDT LIMITED (IN) 2017-02-14 — — US disclosed
US-20160311941-A1 PROCESS FOR THE PREPARATION OF COLESEVELAM CHEMI S.P.A. (IT) 2016-10-27 — — US disclosed
US-20160311941-A1 PROCESS FOR THE PREPARATION OF COLESEVELAM CHEMI S.P.A. (IT) 2016-10-27 — — US disclosed
US-8524212-B2 Prophylactic and/or therapeutic drug for nonalcoholic steatohepatitis MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-09-03 — — US disclosed
US-20130034607-A1 TABLET MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-02-07 — — US disclosed
US-8173114-B2 An agent for promoting excretion of an accumulative chlorine compound comprising a pharmaceutically acceptable anion exchange resin, which is a novel agent that is for promoting the excretion of an accumulative chlorine compound and is MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-05-08 — — US disclosed
US-20110159087-A1 Crosslinked Polymers USV LIMITED (IN) 2011-06-30 — — US disclosed
US-7879869-B2 Anion exchange resins e.g. colestimide; anticholesterol and antidiabetic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-02-01 — — US disclosed
US-20100055066-A1 Agent for prophylactic and/or therapeutic treatment of diabetes MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-03-04 — — US disclosed
US-20090252794-A1 TABLET MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-10-08 — — US disclosed
US-20090162311-A1 Agent for Prevention and/or Treatment of Glomerulopathy MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-06-25 — — US disclosed
US-20090110655-A1 PROPHYLACTIC AND/OR THERAPEUTIC DRUG FOR NONALCOHOLIC STEATOHEPATITIS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-30 — — US disclosed
US-20070212325-A1 Insulin Resistance-Improving Agent MITSUBISHI PHARMA CORPORATION (JP) 2007-09-13 — — US disclosed
US-7199160-B2 Antiobestic agents and health foods MITSUBISHI PHARMA CORPORATION (JP) 2007-04-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090110655-A1 PROPHYLACTIC AND/OR THERAPEUTIC DRUG FOR NONALCOHOLIC STEATOHEPATITIS SLC10A1, SLC10A2, FABP1 TSHR 3325/4885ALDH1A1 936/4885ANPEP 496/4885
US-20090252794-A1 TABLET SLC10A2, SI, TMPRSS15 TSHR 2032/4885ALDH1A1 4627/4885ANPEP 1190/4885
US-20070212325-A1 Insulin Resistance-Improving Agent GPR119, SLC2A8, IAPP TSHR 638/4885ALDH1A1 4273/4885ANPEP 458/4885
US-20090162311-A1 Agent for Prevention and/or Treatment of Glomerulopathy REN, ATP6V1B1, GLS TSHR 4680/4885ALDH1A1 3690/4885ANPEP 199/4885
US-20130034607-A1 TABLET SLC10A2, SI, TMPRSS15 TSHR 2032/4885ALDH1A1 4627/4885ANPEP 1190/4885
US-20100055066-A1 Agent for prophylactic and/or therapeutic treatment of diabetes GPR119, IAPP, GSTO1 TSHR 1270/4885ALDH1A1 1238/4885ANPEP 738/4885
US-20110159087-A1 Crosslinked Polymers SLC10A1, CETP, SLC10A2 TSHR 4554/4885ALDH1A1 2192/4885ANPEP 2981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.